HCQ Shows Promise in Reducing Proteinuria in Primary Glomerular Diseases: Study
A new study published in BMC Nephrology found that hydroxychloroquine (HCQ) therapy demonstrated a trend toward reducing proteinuria in patients with primary glomerular diseases. Importantly, HCQ did not significantly impact estimated glomerular filtration rate (eGFR), indicating preserved kidney function during treatment. The study also highlighted HCQ’s favorable safety profile, making it a promising adjunct therapy in managing proteinuria in these patients.
Proteinuria is a key marker of kidney damage in glomerular diseases and is linked to progression to chronic kidney failure. Conventional treatments often involve immunosuppressants with variable efficacy and potential adverse effects. The potential role of HCQ, traditionally used in autoimmune conditions, offers an alternative pathway targeting inflammatory and immunological mechanisms involved in glomerular injury.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.